Role of advanced glycation end-products in obesity-related ovarian dysfunction

Minerva Endocrinologica

Volumn 39, Issue 3, 2014, Pages 167-174

  Merhi, Z ^a   McGee, E A ^a   Buyuk, E ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Advanced glycosylation end product receptor; Glycosylation end products, advanced; Obesity; Ovary

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOSE TRANSPORTER 4; GLYCOSYLATED ALBUMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID; STARCH; SUGAR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; MUELLERIAN INHIBITING FACTOR; TUMOR ANTIGEN;

ARTICLE; CELL MEMBRANE; CLINICAL STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GLYCOLYSIS; HUMAN; INFLAMMATION; NONHUMAN; OBESITY; OVARY FOLLICLE; OVARY FOLLICLE FLUID; OVARY INSUFFICIENCY; OXIDATIVE STRESS; POSITIVE FEEDBACK; PROTEIN BINDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANOVULATION; BLOOD; COMPLICATION; FEMALE; FERTILIZATION IN VITRO; INFERTILITY, FEMALE; METABOLISM; OVARY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY OUTCOME; SOLUBILITY; TUMOR MICROENVIRONMENT; WESTERN DIET;

ANOVULATION; ANTI-MULLERIAN HORMONE; ANTIGENS, NEOPLASM; CELLULAR MICROENVIRONMENT; DIET, WESTERN; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR FLUID; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFERTILITY, FEMALE; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES; OBESITY; OVARY; OXIDATIVE STRESS; PREGNANCY; PREGNANCY OUTCOME; SOLUBILITY;

EID: 84913543870     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
2. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007;14:482-7.
3. Merhi Z, Buyuk E, Berger DS, et al. Leptin suppresses anti-Mullerian hormone gene expression through the JAK2/STAT3 pathway in luteinized granulosa cells of women undergoing IVF. Hum Reprod 2013;28:1661-9.
4. Merhi ZO. Weight loss by bariatric surgery and subsequent fertility. Fertil Steril 2007;87:430-2.
5. Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril 2009;92:1501-8.
6. Rich-Edwards JW, Spiegelman D, Garland M, Hertz-mark E, Hunter DJ, Colditz GA et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 2002;13:184-90.
7. Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review. Seminars in reproductive medicine 2011;29:507-13.
8. Marshall NE, Spong CY. Obesity, pregnancy complications, and birth outcomes. Seminars in reproductive medicine 2012;30:465-71.
9. Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Hum Reprod 2007;22:414-20.
10. van der Steeg JW, Steures P, Eijkemans MJ, Habbema JD, Hompes PG, Burggraaff JM et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod 2008;23:324-8.
11. Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertil Steril 2011;95:2364-8.
12. Tamer Erel C, Senturk LM. The impact of body mass index on assisted reproduction. Curr Opin Obstet Gynecol 2009;21:228-35.
13. Leuner B, Max M, Thamm K, Kausler C, Yakobus Y, Bierhaus A et al. RAGE influences obesity in mice. Effects of the presence of RAGE on weight gain, AGE accumulation, and insulin levels in mice on a high fat diet. Z Gerontol Geriatr 2012;45:102-8.
14. Merhi Z. Advanced glycation end products and their relevance in female reproduction. Hum Reprod 2014;29:135-45.
15. Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab 2012;97:2231-42.
16. Song F, Hurtado Del Pozo C, Rosario R, Zou YS, Ananthakrishnan R, Xu X et al. RAGE Regulates the Metabolic and Inflammatory Response to High Fat Feeding in Mice. Diabetes 2014;63:1948-65.
17. Vazzana N, Guagnano MT, Cuccurullo C, Ferrante E, Lattanzio S, Liani R et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J Clin Endocrinol Metab 2012;97:E1726-30.
18. Merhi Z, Irani M, Doswell AD, Ambroggio J. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab 2014;99:E226-33.
19. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Current pharmaceutical design 2008;14:987-9.
20. Brownlee M, Cerami A, Vlassara H. Advanced gly-cosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21.
21. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Current diabetes reviews 2005; 1:93-106.
22. Diamanti-Kandarakis E, Piperi C, Patsouris E, Kor-kolopoulou P, Panidis D, Pawelczyk L et al. Immu-nohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007;127:581-9.
23. Tatone C, Amicarelli F. The aging ovary-the poor granulosa cells. Fertil Steril 2013;99:12-7.
24. Park JH, Choi TS. Polycystic ovary syndrome (PCOS)-like phenotypes in the d-galactose-induced aging mouse model. Biochem Biophys Res Commun 2012;427:701-4.
25. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl) 2007;85:1413-20.
26. Tatone C, Eichenlaub-Ritter U, Amicarelli F. Dicarbo-nyl stress and glyoxalases in ovarian function. Biochem Soc Trans 2014;42:433-8.
27. Inagi R. Inhibitors of advanced glycation and en-doplasmic reticulum stress. Methods Enzymol 2011;491:361-80.
28. Ramasamy R, Yan SF, Schmidt AM. The diverse lig-and repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012;57:160-7.
29. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001;276:3195-202.
30. Rudijanto A. The expression and down stream effect of lectin like-oxidized low density lipoprotein 1 (LOX-1) in hyperglycemic state. Acta Med Indones 2007;39:36-43.
31. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995;230:408-15.
32. Lai KN, Leung JC, Chan LY, Li FF, Tang SC, Lam MF et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004;138:466-75.
33. Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J et al. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol (Baltimore, Md:1950) 2008;181:1499-506.
34. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for SlOO/calgranulin polypeptides. Cell 1999;97:889-901.
35. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced car-diomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008;102:1239-46.
36. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
37. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007;7:743-51.
38. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sei (London, England:1979) 2009;116:621-37.
39. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
40. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006;30:13-7.
41. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creat-sas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005;62:37-43.
42. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716-27.
43. Zhang L, Bukulin M, Kojro E, Roth A, Metz W, Fahrenholz F et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008;283:35507-16.
44. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008;22:1572-80.
45. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109.
46. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:109-14.
47. Nakamura K, Yamagishi S, Adachi H, Kurita-Naka-mura Y, Matsui T, Yoshida T et al. Serum levels of s RAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13:185-9.
48. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-91.
49. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003;14:728-31.
50. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by amino-guanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999;48:1308-15.
51. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Aes-sopos A, Paterakis T, Katsikis I et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007;56:129-34.
52. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66:103-9.
53. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sei Med Sei 2007;62:427-33.
54. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sei U S A 2002;99:15596-601.
55. Luevano-Contreras C, Garay-Sevilla ME, Wrobel K, Malacara JM, Wrobel K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 2013;52:22-6.
56. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Götting C et al. Effects of low-and high-advanced glycation endproduct meals on macro-and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. AmJ Clin Nutr 2007;85:1236-43.
57. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011;34:1610-6.
58. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H et al. Expression profiling of endogenous secretory receptor for advanced gly-cation end products in human organs. Mod Pathol 2005;18:1385-96.
59. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glyca-tion endproducts. Nat Med 1998;4:1025-31.
60. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-35.
61. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzi-goli E, Casolaro A et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycémie control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-34.
62. Choi KM, Han KA, Ahn HJ, Hwang SY, Hong HC, Choi HY et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012;97:3751-8.
63. Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009;132.96-101.
64. Marsche G, Weigle B, Sattler W, Malle E. Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J 2007;21:3075-82.
65. Jia X, Chang T, Wilson TW, Wu L. Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Aktl. PloS one 2012;7:e366l0.
66. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996;27:565-73.
67. Fujii EY, Nakayama M. The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging. Fertil Steril 2010;94:694-700.
68. Diamanti-Kandarakis E, Livadas S, Kandaraki E, Papa-georgiou E, Koutsilieris M. Interference of AGE-RAGE signaling with steroidogenic enzyme action in human ovarian cells. Endocrine Society, San Francisco, CA 2013.
69. Piperi C, Koutsilieris M, Diamanti-Kandarakis E. Advanced glycation end-products inhibit insulin signaling in human granulosa cells: a causative link to PCOS pathogenesis. Endocrine Society, San Francisco, CA 2013.
70. Sutton-McDowall ML, Gilchrist RB, Thompson JG. The pivotal role of glucose metabolism in determining oocyte developmental competence. Reproduction 2010;139:685-95.
71. Tatone C, Heizenrieder T, Di Emidio G, Treffen P, Amicarelli F, Seidel T et al. Evidence that carbon-yl stress by methylglyoxal exposure induces DNA damage and spindle aberrations, affects mitochondrial integrity in mammalian oocytes and contributes to oocyte ageing. Hum Reprod 2011;26:1843-59.
72. Jinno M, Takeuchi M, Watanabe A, Teruya K, Hi-rohama J, Eguchi N et al. Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod 2011;26:6O4-10.
73. Ambroggio J. CP, Merhi Z. Soluble receptor for advanced glycation end-products (sRAGE): A potential indicator of ovarian response to controlled ovarian hyperStimulation. American Society for Reproductive Medicine, Boston, MA 2013.